EUVIMEDEUVIMED entdecken
Crossref

The 340B Drug Pricing Program at a Crossroads

Ryan P Knox, Ameet Sarpatwari

JAMA · 16.06.2026 · 335 (23) · 2009

DOI: 10.1001/jama.2026.6812 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, erschienen am 16.06.2026. Verfasst von Ryan P Knox und 1 weiteren Autor:innen. Beteiligte Einrichtung: DePaul University College of Law, Chicago, Illinois. Die Arbeit nennt 9 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This Viewpoint presents the history of the Health Resources & Services Administration (HRSA) 340B Drug Pricing Program and 340B Rebate Model Pilot Program, summarizes their controversies and limitations, and calls for action by Congress and HRSA to address these issues and strengthen support for safety-net hospitals and clinics.

Autor:innen und Institutionen

  • DePaul University College of Law, Chicago, Illinois.
  • Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, Massachusetts.

Zitieren

APA

Knox, R. P., & Sarpatwari, A. (2026). The 340B Drug Pricing Program at a Crossroads. JAMA, 335(23), 2009. https://doi.org/10.1001/jama.2026.6812

Vancouver

Knox RP, Sarpatwari A. The 340B Drug Pricing Program at a Crossroads. JAMA. 2026;335(23):2009. doi:10.1001/jama.2026.6812

BibTeX
@article{Knox2026,
  author = {Knox, Ryan P and Sarpatwari, Ameet},
  title = {The 340B Drug Pricing Program at a Crossroads},
  journal = {JAMA},
  year = {2026},
  volume = {335},
  number = {23},
  pages = {2009},
  doi = {10.1001/jama.2026.6812}
}
Kostenlos starten →